Congenital Afibrinogenemia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Congenital afibrinogenemia (CAF) is a sporadic genetic coagulation disorder marked by the near absence of plasma fibrinogen (factor I), a crucial protein for blood clotting. This condition can result in bleeding that ranges from mild to severe and can affect various body parts, including the gastrointestinal tract, cranial vault, central nervous system, joints, bones, liver, and spleen. About 20% of CAF patients may develop hemarthrosis, a symptom that can sometimes be confused with hemophilia. While individuals with congenital afibrinogenemia typically experience symptoms from early infancy, those with hypofibrinogenemia (fibrinogen levels below 100 mg/dL) may present with minor bleeding issues at a later stage. Due to the impaired coagulability of their blood, CAF patients are at a high risk of severe bleeding during surgery or other medical procedures. Diagnosis of this condition involves genetic testing, blood coagulation tests, and assessment of fibrinogen levels.

·       Congenital afibrinogenemia is a sporadic condition occurring in roughly 1 in 1 million newborns.

 

Thelansis’s “Congenital Afibrinogenemia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Congenital Afibrinogenemia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Congenital Afibrinogenemia across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Congenital Afibrinogenemia Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Congenital Afibrinogenemia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Congenital Afibrinogenemia, Congenital Afibrinogenemia market outlook, Congenital Afibrinogenemia competitive landscape, Congenital Afibrinogenemia market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)